Journal
NATURE COMMUNICATIONS
Volume 7, Issue -, Pages -Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/ncomms12791
Keywords
-
Categories
Funding
- US National Institutes of Health Prostate Specialized Program of Research Excellence grant [P50CA186786]
- Early Detection Research Network grant [UO1 CA111275]
- US National Institutes of Health [R01 CA132874, RO1 CA154365]
- US Department of Defense [PC100171]
- Prostate Cancer Foundation
- Howard Hughes Medical Institute
- Prostate Cancer Foundation Young Investigator Award
- US Department of Defense Post-Doctoral Fellowship [W81XWH-13-1-0284]
- University of Michigan Cellular and Molecular Biology National Research Service Award Institutional Predoctoral Training Grant
Ask authors/readers for more resources
Molecular classification of cancers into subtypes has resulted in an advance in our understanding of tumour biology and treatment response across multiple tumour types. However, to date, cancer profiling has largely focused on protein-coding genes, which comprise <1% of the genome. Here we leverage a compendium of 58,648 long noncoding RNAs (lncRNAs) to subtype 947 breast cancer samples. We show that lncRNA-based profiling categorizes breast tumours by their known molecular subtypes in breast cancer. We identify a cohort of breast cancer-associated and oestrogen-regulated lncRNAs, and investigate the role of the top prioritized oestrogen receptor (ER)-regulated lncRNA, DSCAM-AS1. We demonstrate that DSCAM-AS1 mediates tumour progression and tamoxifen resistance and identify hnRNPL as an interacting protein involved in the mechanism of DSCAM-AS1 action. By highlighting the role of DSCAM-AS1 in breast cancer biology and treatment resistance, this study provides insight into the potential clinical implications of lncRNAs in breast cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
